Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.
Soleno Therapeutics’ stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.